or Try an Advanced Search...

    Technical Analysis for ITOS - iTeos Therapeutics, Inc.

    Grade Last Price % Change Price Change
    F 8.81 4.26% 0.36
    ITOS closed up 4.26 percent on Friday, November 1, 2024, on 1.14 times normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
    Earnings due: Nov 5
    *** please verify all earnings dates ***
    1 Watcher
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Strong Down Down Up
    Historical ITOS trend table...
    Date Alert Name Type % Chg
    Oversold Stochastic Weakness 0.00%
    New 52 Week Closing Low Bearish 4.26%
    New 52 Week Low Weakness 4.26%
    Oversold Stochastic Weakness 4.26%
    New 52 Week Low Weakness 2.56%
    Oversold Stochastic Weakness 2.56%
    New 52 Week Closing Low Bearish 2.68%
    180 Bearish Setup Bearish Swing Setup 2.68%
    Reversal New Lows Setup Bearish Swing Setup 2.68%
    Outside Day Range Expansion 2.68%
    Older End-of-Day Signals for ITOS ...

       Recent Intraday Alerts

    Alert Time
    Up 5% about 20 hours ago
    Rose Above Previous Day's High about 20 hours ago
    10 DMA Resistance about 23 hours ago
    60 Minute Opening Range Breakout about 23 hours ago
    Rose Above 10 DMA about 23 hours ago
    View Earlier Intraday Alerts

    Get a Trading Sidekick!

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Track My Stocks
    Configure default chart indicators
    ITOS Chart by TradingView
    Basic chart:

    Profile

    Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for cancer patients. Its product pipeline includes EOS-850, a small molecule antagonist of the adenosine A2a receptor; and EOS-448, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains. The company was founded in 2011 and is based in Cambridge, Massachusetts with an additional location in Gosselies, Belgium.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Biotechnology Biopharmaceutical Cancer Life Sciences Adenosine Therapeutics For Cancer

    Is ITOS a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Oct 24 iTeos Therapeutics to Highlight Inupadenant Preclinical, Translational, and Phase 2 A2A-005 Clinical Trial Data in 2L NSCLC at ESMO Immuno-Oncology Congress
    Sep 16 Nuvalent Flies On 'Multibillion-Dollar' Potential, While Iteos Crashes On Patient Deaths
    Sep 16 Crude Oil Surges Over 1%; Instil Bio Shares Plunge
    Sep 16 Why Exicure Shares Are Trading Higher By Over 49%; Here Are 20 Stocks Moving Premarket
    Sep 16 ESMO 2024: TIGIT race tightens with first look at GSK/iTeos’s TIGIT in NSCLC
    Sep 15 iTeos Therapeutics: ESMO Data Showing Signs Of A Real Win For TIGIT
    Sep 14 TIGIT drug from iTeos shrinks lung tumors in trial
    Sep 14 GSK, iTeos lung cancer therapy outperforms Jemperli in mid-stage trial
    Sep 14 iTeos Announces Clinically Meaningful Objective Response Rate Observed at Every Dose in Follow-up Interim Analysis of GALAXIES Lung-201 Study of Belrestotug + Dostarlimab in First-Line, PD-L1 High Non-Small Cell Lung Cancer Patients
    Aug 28 iTeos to Participate in Upcoming Investor Conferences
    See more ITOS news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 18.75
    52 Week Low 8.41
    Average Volume 730,837
    200-Day Moving Average 13.16
    50-Day Moving Average 11.81
    20-Day Moving Average 9.14
    10-Day Moving Average 8.76
    Average True Range 0.55
    RSI (14) 36.31
    ADX 31.3
    +DI 14.52
    -DI 23.43
    Chandelier Exit (Long, 3 ATRs) 8.58
    Chandelier Exit (Short, 3 ATRs) 10.05
    Upper Bollinger Bands 10.02
    Lower Bollinger Band 8.26
    Percent B (%b) 0.31
    BandWidth 19.33
    MACD Line -0.78
    MACD Signal Line -0.91
    MACD Histogram 0.1294
    Fundamentals Value
    Market Cap 315.27 Million
    Num Shares 35.8 Million
    EPS -1.75
    Price-to-Earnings (P/E) Ratio -5.03
    Price-to-Sales 5.87
    Price-to-Book 0.64
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 9.56
    Resistance 3 (R3) 9.52 9.22 9.44
    Resistance 2 (R2) 9.22 9.03 9.25 9.39
    Resistance 1 (R1) 9.02 8.91 9.12 9.06 9.35
    Pivot Point 8.72 8.72 8.78 8.75 8.72
    Support 1 (S1) 8.52 8.53 8.62 8.56 8.27
    Support 2 (S2) 8.22 8.41 8.25 8.23
    Support 3 (S3) 8.02 8.22 8.19
    Support 4 (S4) 8.06